1. CTLA-4 gene polymorphisms associate with efficacy of postoperative radioiodine-131 for differentiated thyroid carcinoma (Retracted)
   De-Feng Chang et al, 2017, Future Oncology CrossRef
2. Lung Metastases From Papillary Thyroid Cancer With Persistently Negative Thyroglobulin and Elevated Thyroglobulin Antibody Levels During Radioactive Iodine Treatment and Follow-Up: Long-Term Outcomes and Prognostic Indicators
   Zhong-Ling Qiu et al, 2020, Frontiers in Endocrinology CrossRef
3. Occult lung metastases of papillary thyroid cancer detected in a resected pulmonary arteriovenous malformation specimen
   Tomoyoshi Inoue et al, 2022, Respiratory Medicine Case Reports CrossRef
4. Preclinical evaluation of a novel engineered recombinant human anti-CD44v6 antibody for potential use in radio-immunotherapy
   Anja Mortensen et al, 2018, International Journal of Oncology CrossRef
5. Efficacy of radioiodine therapy for treating 20 patients with pulmonary metastases from differentiated thyroid cancer and a meta-analysis of the current literature
   X. Zhang et al, 2018, Clinical and Translational Oncology CrossRef
6. Delay of initial radioactive iodine therapy beyond 3 months has no effect on clinical responses and overall survival in patients with thyroid carcinoma: A cohort study and a meta‐analysis
   Fang Cheng et al, 2022, Cancer Medicine CrossRef
7. Therapeutic response and long-term outcome of differentiated thyroid cancer with pulmonary metastases treated by radioiodine therapy
   Jing Yang et al, 2017, Oncotarget CrossRef
8. Iodine-131: An Effective Method for Treating Lymph Node Metastases of Differentiated Thyroid Cancer
   Ying He et al, 2016, Medical Science Monitor CrossRef